Item 1.01 Entry into a Material Definitive Agreement





On January 6, 2021, Tricida, Inc. (the "Company"), as borrower, Hercules
Capital, Inc., as administrative agent (in such capacity, the "Agent"), and each
of the financial institutions party thereto as lenders (the "Lenders") entered
into the Sixth Amendment to Loan and Security Agreement ("Sixth Amendment") to
amend certain terms of the Loan and Security Agreement, dated as of February 28,
2018 (as amended by that certain First Amendment to Loan and Security Agreement
and First Amendment to Warrants dated as of April 10, 2018, that certain Second
Amendment to Loan and Security Agreement, dated as of October 15, 2018, that
certain Third Amendment to Loan and Security Agreement, dated as of March 27,
2019, that certain Fourth Amendment to Loan and Security Agreement, dated as of
March 31, 2020, that certain Fifth Amendment to Loan and Security Agreement,
dated as of May 18, 2020 and the Sixth Amendment, the "Loan Agreement", and the
term loans thereunder, the "Term Loan") by and among the Company, the Agent and
the Lenders. The Sixth Amendment provides for, among other things, a decrease in
the amount available under the Loan Agreement from $200.0 million to $75.0
million. The loan repayment schedule provides for interest only payments until
April 1, 2022 (the "Amortization Date"), followed by consecutive equal monthly
amortization payments of principal and interest through the maturity date. The
maturity date of the Loan Agreement is October 1, 2023, subject to extension to
April 1, 2024 on the condition that the Company obtains final approval from the
U.S. Food and Drug Administration ("FDA") for the New Drug Application ("NDA")
for veverimer (also known as TRC101) (such final approval, the "TRC101
Approval") on or before October 1, 2023. The Sixth Amendment also eliminates the
1.0% prepayment charge for prepayments of principal of the Term Loan made after
March 1, 2021.
The Sixth Amendment modifies certain covenants applicable to the Company under
the Loan Agreement. Under the terms of the Sixth Amendment, the Company is
required to at all times maintain unrestricted cash in an amount not less than
100% of the outstanding principal amount of the Term Loan, until the achievement
of statistically significant positive data from the completion of either of the
two interim analyses for efficacy (to be performed when approximately 150 and
250 subjects have had a positively adjudicated primary endpoint event) as
described in Borrower's Clinical Study Protocol TRCA-303 (VALOR-CKD) for
veverimer, Amendment 2, dated November 18, 2020, of the ongoing VALOR-CKD trial,
which, along with an acceptable safety profile, would support re-filing of the
NDA for veverimer with the FDA, subject to verification by the Agent. From and
after achievement of such positive data, the Company is required to at all times
maintain unrestricted cash in an amount equal to 75% of the outstanding
principal amount of the Term Loan until achievement of the TRC101 Approval,
whereupon such unrestricted cash maintenance covenants shall cease to apply.
The Sixth Amendment reduces, from $500.0 million to $300.0 million, the minimum
market capitalization of the Company that triggers a covenant of the Company to
deliver to the Agent monthly financial statements and related reporting.
The foregoing description of the Sixth Amendment and the Loan Agreement does not
purport to be complete and is qualified in its entirety by reference, as
applicable, to the full text of the Amendment, including exhibits attached
thereto, a copy of which is attached hereto as Exhibit 10.1, in each case to
this Current Report on Form 8-K, which is incorporated herein by reference.
Item 2.03          Creation of a Direct Financial Obligation or an Obligation under an
                   Off-Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Amendment is incorporated by reference into this Item 2.03. Item 9.01 Financial Statements and Exhibits.

--------------------------------------------------------------------------------



(d) Exhibits.

Exhibit Number              Description

                              Sixth Amendment to Loan and Security

Agreement, dated as of January 6,


                            2021 among Tricida, Inc., Hercules Capital Inc. and the several banks and
                            other financial institutions or entities from time to time parties
10.1                        thereto.

                            Cover Page Interactive Data File (embedded within the Inline XBRL
104                         document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses